Evaluation With CT Scan of Possible Changes in Airways After Treatment With Daxas® in Severe Chronic Obstructive Pulmonary Disease Patients

Inclusion Criteria: * Male or female patient ≥ 30 years old * Patient with BMI ≥ 20 * Written informed consent obtained * Female patient of childbearing potential who confirm that a contraception method was used at least 14 days before visit 1 and will continue to use a contraception method during the study. * Patient should be treated according to GOLD guidelines * COPD patient with GOLD stages III until IV * Patient with smoking history of at least 10 pack-years * Patient takes Spiriva® and a fixed combination of inhaled steroids and long acting beta agonist (LABA) at least 6 weeks before visit 1 * Patient must be able to understand and complete the protocol requirements, instructions, questionnaires and protocol-stated restrictions. Exclusion Criteria: * Pregnant or lactating females * Patient with severe immunological diseases and/ or severe acute infectious diseases. * Patient with heart failure * Patient with diagnosis of cancer (except basal cell carcinoma) * Patient with a history of depression associated with suicidal ideation or behaviour * Patient with moderate or severe hepatic impairment. * Patient with lactose intolerance * Patient is unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study. * Patient who received any investigational new drug within the last 4 weeks prior to the screening visit or twice the duration of the biological effect of any drug (whichever is longer).